MarginsXMarginsX
Home › Markets › Health Care › ETON

Eton Pharmaceuticals Inc. (ETON)

ETON trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$63.88
-0.08% on the day
Market cap
$1.8B
Small cap
Revenue · 2025
$80.0M
+104.9% on 2024
Net income · 2025
-$4.6M
-5.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/0001437749-26-009059-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerETON on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001710340
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$80.0M
Net income-$4.6M
Operating income-$844K
Net margin-5.8%
Operating margin-1.1%
Revenue growth+104.9%
Cash$25.9M
Total assets$92.1M
P/E (computed)Net income was not positive
P/S (computed)23.0×

Warning signs

Cash runway
Cash-flow positive
$55.6M cash at September 30, 2026
Share count, 1 year
+7.5%
2025-11-05 to 2026-11-02 · +12.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$25.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$55.6M cash; operating cash flow $9.6M a quarter.Report 2026-09-30
Shares outstanding28,842,215 (2026-11-02); 26,817,535 a year earlier; 25,658,396 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Chicago, Illinois, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $25.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$57.9M$35.2M$35.2M$55.6M$23.1M$141.1M10-Q 2026-11-05
Q2 2026
2026-06-30
$37.6M$11.6M$7.3M$26.8M$27.9M$105.6M10-Q 2026-08-13
Q1 2026
2026-03-31
$24.3M$1.6M$7.4M$19.7M$30.7M$86.9M10-Q 2026-05-14
Q4 2025
2025-12-31
$21.3M$1.5M-$11.6M$25.9M$30.6M$80.0M10-K 2026-03-19
Q3 2025
2025-09-30
$22.5M-$1.9M$12.0M$37.1M$30.4M$70.3M10-Q 2026-11-05
Q2 2025
2025-06-30
$18.9M-$2.6M$8.0M$25.4M$30.2M$58.2M10-Q 2026-08-13
Q1 2025
2025-03-31
$17.3M-$1.6M$2.1M$17.4M$30.0M$48.3M10-Q 2026-05-14
Q4 2024
2024-12-31
$11.6M-$598K-$765K$14.9M$29.8M$39.0M10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52024-12-12
Latest annual report
FORM 10-K
10-K2026-03-19
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxy
FORM DEF 14A
DEF 14A2026-04-24

Source: SEC EDGAR submissions feed, 427 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+13.2%
1 month+19.9%
3 months+56.7%
Year to date+278.1%
1 year+278.7%
From 52-week high-6.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZYMEZymeworks Inc.$26.45+0.80%$1.8B
AGIOAgios Pharmaceuticals Inc.$30.15-4.56%$1.8B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
BRVEBraveheart Bio Inc.$19.49-0.66%$1.8B
STOKStoke Therapeutics Inc.$26.63-0.19%$1.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier